Summary
Celtic Biotech Ireland has developed CB24(Crotoxin). A naturally derived receptor binding protein, delivered as monotherapy at home using infusion pumps, is hailed as a life changing treatment of Non-Small Cell Lung Cancer (NSCLC). Delivered intravenously, CB24 induces predictable and consistent apoptosis (cell death) and autophagy (degradation) in human lung carcinoma cells. CB24 outclass the competitive NSCLC treatment solutions (surgery, chemotherapy, and radiotherapy) through its efficacy, safety, minimal side-effects, easy to use home based treatment and suitability for all patients including those at stage 3 & 4.
Celtic have already proven the efficacy of CB24 through pre-clinical and FIH clinical trials.
Through the proposed 24months EIC project, the company aims to undertake Phase I Part 3 clinical trials involving 24 patients with the ultimate goal of garnering the regulatory approvals (EMA, FDA) to market the drug as a verified cancer therapeutic.
Celtic have already proven the efficacy of CB24 through pre-clinical and FIH clinical trials.
Through the proposed 24months EIC project, the company aims to undertake Phase I Part 3 clinical trials involving 24 patients with the ultimate goal of garnering the regulatory approvals (EMA, FDA) to market the drug as a verified cancer therapeutic.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/190166095 |
| Start date: | 01-10-2023 |
| End date: | 30-09-2025 |
| Total budget - Public funding: | 3 855 337,50 Euro - 2 499 999,00 Euro |
Cordis data
Original description
Celtic Biotech Ireland has developed CB24(Crotoxin). A naturally derived receptor binding protein, delivered as monotherapy at home using infusion pumps, is hailed as a life changing treatment of Non-Small Cell Lung Cancer (NSCLC). Delivered intravenously, CB24 induces predictable and consistent apoptosis (cell death) and autophagy (degradation) in human lung carcinoma cells. CB24 outclass the competitive NSCLC treatment solutions (surgery, chemotherapy, and radiotherapy) through its efficacy, safety, minimal side-effects, easy to use home based treatment and suitability for all patients including those at stage 3 & 4.Celtic have already proven the efficacy of CB24 through pre-clinical and FIH clinical trials.
Through the proposed 24months EIC project, the company aims to undertake Phase I Part 3 clinical trials involving 24 patients with the ultimate goal of garnering the regulatory approvals (EMA, FDA) to market the drug as a verified cancer therapeutic.
Status
SIGNEDCall topic
HORIZON-EIC-2023-ACCELERATOROPEN-01Update Date
12-03-2024
Geographical location(s)
